Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-03-16 | JAMES C. MULLEN: Age 52; Principal Occupation: Chief Executive Officer of Patheon Inc., a global provider of contract development and manufacturing services to the pharmaceutical and biotechnology industries based in Toronto, Canada. Director of PerkinElmer since 2004. Chair of the nominating and corporate governance committee and a member of the compensation and benefits committee. |
| 2012-03-14 | James C. Mullen: Age 53; Principal Occupation: Chief Executive Officer of Patheon Inc., a global provider of contract development and manufacturing services to the pharmaceutical and biotechnology industries based in Toronto, Canada. Director of PerkinElmer since 2004. Chair of the nominating and corporate governance committee and a member of the compensation and benefits committee. |
| 2013-03-13 | James C. Mullen Age 54; Principal Occupation: Chief Executive Officer of Patheon Inc., a global provider of contract development and manufacturing services to the pharmaceutical and biotechnology industries based in Toronto, Canada. Director of PerkinElmer since 2004. Member of the audit and compensation and benefits committees. |
| 2014-03-12 | James C. Mullen, Age 55; Principal Occupation: Chief Executive Officer of Patheon Inc. Director of PerkinElmer since 2004. Member of the audit and compensation and benefits committees. 2013 Director Compensation: $235,014 total. |
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-09 | James C. Mullen Former Chief Executive Officer, Patheon N.V. and Former Chief Executive Officer, Biogen Inc. Strategy and Finance Summary Director Compensation Table James C. Mullen Fees Earned or Paid in Cash: $18,481 Stock Awards: $0 All Other Compensation: $0 Total: $18,481 Proxy Statement 2019 |
| 2020-04-07 | James C. Mullen Independent Former Chief Executive Officer, Patheon N.V. and Former Chief Executive Officer, Biogen Inc. Age: 61 Director since: 2018 Committees: Strategy and Finance Summary director compensation table Total: $320,615 |
| 2021-04-08 | James C. Mullen Age: 62 Director since: 2018 Committees: Strategy and Finance ... Summary director compensation table ... James C. Mullen Fees Earned or Paid in Cash $125,000 Stock Awards $195,138 All Other Compensation $535 Total $320,673 |
| 2022-04-07 | James C. Mullen Age: 63 Director since: 2018 Committees: Strategy and Finance Director summary compensation table James C. Mullen $125,000 Fees Earned or Paid in Cash, $200,144 Stock Awards, $490 All Other Compensation, Total $325,634. |
| 2023-04-07 | James C. Mullen Age: 64 Director since: 2018 Committees: Strategy and Finance Mr. Mullen brings valuable industry knowledge to the Board. |
| 2024-04-09 | Mr. Mullen previously served as Executive Chair of the Board of Directors of Editas Medicine. |
| 2025-04-08 | James C. Mullen Independent Age: 66 Director since: 2018 Committees: Compensation, Strategy and Finance PROFESSIONAL HIGHLIGHTS • Editas Medicine, Inc. • Executive Chair of the Board (2022 - 2023) • Chairman, President and Chief Executive Officer (2021 - 2022) • Chief Executive Officer, Patheon N.V. (2011 - 2017) • Chief Executive Officer, Biogen Inc. (2000 - 2010) OTHER CURRENT DIRECTORSHIPS: • None PREVIOUSLY HELD DIRECTORSHIPS: • Editas Medicine, Inc., Insulet Inc. and Patheon N.V. DIRECTOR QUALIFICATIONS Mr. Mullen previously served as Executive Chair of the Board of Directors of Editas Medicine, a clinical-stage biotechnology company, as Chief Executive Officer of Patheon N.V., a contract development and manufacturing organization which was acquired by the Company in 2017, and as Chief Executive Officer of Biogen Inc. Due to his 35-plus years of senior leadership experience in the pharmaceutical and biotechnology industries, he brings to the Board valuable industry knowledge and industry-specific strategic leadership skills. Mr. Mullen also brings valuable board-level experience from his many years serving on public company boards in the pharmaceutical industry. Director compensation table shows total compensation of $325,836. |
Data sourced from SEC filings. Last updated: 2025-08-30